<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159802">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942694</url>
  </required_header>
  <id_info>
    <org_study_id>U01DK098245</org_study_id>
    <secondary_id>U01DK098245</secondary_id>
    <nct_id>NCT01942694</nct_id>
  </id_info>
  <brief_title>Vitamin D and Type 2 Diabetes Study</brief_title>
  <acronym>D2d</acronym>
  <official_title>Vitamin D and Type 2 Diabetes Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the Vitamin D and type 2 diabetes (D2d) study is to determine if vitamin D
      supplementation works to delay the onset of type 2 diabetes in people at risk for the
      disease and to gain a better understand how vitamin D affects glucose (sugar) metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the Vitamin D and type 2 diabetes (D2d) study is to determine if vitamin D
      supplementation works to delay the onset of type 2 diabetes in people at risk for the
      disease and to gain a better understand how vitamin D affects glucose (sugar) metabolism.
      Researchers at twenty US sites will enroll people with pre-diabetes (people who have higher
      than normal blood glucose level but not high enough to meet the diagnosis of diabetes).  The
      study will enroll participants over approximately 2 years and participants will be followed
      for approximately 4 years.  Participants will receive either Vitamin D or a placebo by
      chance.  Participants will take 1 pill a day for the duration of the study.  Participants
      will visit the study site for up to 13 scheduled visits during their participation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Time to development of diabetes</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of plasma 25OHD concentration.</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of the safety of vitamin D supplementation.</measure>
    <time_frame>Every 3 months for approximately 48 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Every 6 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of response to vitamin D supplementation by baseline characteristic: BMI</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of response to vitamin D supplementation by baseline characteristic: waist circumference</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of response to vitamin D supplementation by baseline characteristic: age</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of response to Vitamin D supplementation by baseline characteristic: geographic location (as a proxy for sun exposure)</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of response to vitamin D supplementation by baseline characteristic: calcium intake</measure>
    <time_frame>every 12 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of response to vitamin D supplementation by baseline characteristic: 25OHD concentration</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of response to vitamin D supplementation by baseline characteristic: race (as a proxy for skin pigmentation)</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who discontinue study pills as a measure of the tolerability of vitamin D supplementation.</measure>
    <time_frame>Every 6 months for approximately 48 months.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG as a continuous variable.</measure>
    <time_frame>Every 6 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2hPG as a continuous variable.</measure>
    <time_frame>Every 12 months for approximately 48 months.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of insulin resistance (derived from the OGTT).</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of beta cell secretion (derived from the OGTT)</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of characteristics associated with the variability in achieved 25-hydroxycholecalciferol (25OHD) concentration.</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c as a continuous variable.</measure>
    <time_frame>Every 6 months for approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2382</enrollment>
  <condition>Prediabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One pill daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D (Cholecalciferol)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One vitamin D pill daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D (Cholecalciferol)</intervention_name>
    <description>Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
    <arm_group_label>Vitamin D (Cholecalciferol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as one soft-gel pill daily by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pre-diabetes (&quot;at increased risk for diabetes&quot;) defined by meeting 2-out-of-3 of the
             following glycemic criteria at the baseline visit:

               1. Fasting plasma glucose (FPG) 100-125 mg/dL

               2. 2-hour plasma glucose (2hPG) 140-199 mg/dL

               3. Hemoglobin A1c (HbA1c) 5.7-6.4%

          2. Age â‰¥ 30 years.

          3. Body Mass Index  22.5 to 42 kg/m2

          4. Provision of signed and dated written informed consent prior to any study procedures.

        Major Exclusion Criteria:

          1. Diabetes based on either of the following criteria:

               1. History (past 1 year) of hypoglycemic pharmacotherapy (oral or injectable
                  medication approved by the FDA for type 2 diabetes), used for any condition
                  (e.g. pre-diabetes, diabetes, polycystic ovarian syndrome.

               2. Meeting the diagnosis criteria for diabetes

          2. History (past 3 years) of hyperparathyroidism, nephrolithiasis or hypercalcemia.

          3. Pregnancy (past 1 year by report or positive pregnancy test at screening), intent to
             become pregnant in the next 4 years or unprotected intercourse. History of
             gestational diabetes is not an exclusion criterion.

          4. Currently breastfeeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anastassios Pittas, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest American Indian Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Meacham</last_name>
      <phone>602-640-2190</phone>
      <phone_ext>204</phone_ext>
      <email>mmeacham@mail.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Jennifer Weil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Ruelas, MSW</last_name>
      <phone>323-361-8416</phone>
      <email>vruelas@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anne Peters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josephine Hau, BS, RD</last_name>
      <phone>650-427-0785</phone>
      <email>jhau@standford.edu</email>
    </contact>
    <investigator>
      <last_name>Sun H Kim, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy Jones, BS, BSN, RN</last_name>
      <phone>407-303-7193</phone>
      <email>TRI@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Richard E Pratley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rincy Varughese, MS</last_name>
      <phone>404-235-3024</phone>
    </contact>
    <investigator>
      <last_name>Lawrence Phillips, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Sullivan, MS</last_name>
      <phone>312-503-3413</phone>
      <email>D2d@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Neff, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Lower, MA</last_name>
      <phone>913-588-6052</phone>
      <email>d2dstudy@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>David C Robbins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Thomassie, RN, CCRC</last_name>
      <phone>225-763-3000</phone>
      <email>clinicaltrials@pbrc.edu</email>
    </contact>
    <investigator>
      <last_name>George Bray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robbin Bye, RN, BSN</last_name>
      <phone>504-988-0200</phone>
      <email>rbye1@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Vivian Fonseca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacki LaPointe, RN</last_name>
      <phone>207-661-7624</phone>
      <email>D2d@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Irwin Brodsky, Md, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Community Clinical Research Center</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest Evans</last_name>
      <phone>301-560-2929</phone>
      <email>studies@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Vanita Aroda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gunn, MS</last_name>
      <phone>617-636-2834</phone>
      <email>tufts@d2dstudy.org</email>
    </contact>
    <investigator>
      <last_name>Anastassios G Pittas, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Partners Riverside Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Cook, RN</last_name>
      <phone>612-341-1950</phone>
    </contact>
    <investigator>
      <last_name>Chhavi Chadha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Rodriguez</last_name>
      <phone>402-995-3924</phone>
      <email>mrodrigu@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Cyrus V Desouza, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Omaha VA Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Heineman</last_name>
      <phone>402-995-4873</phone>
      <email>mrodrigu@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Cyrus Desouza, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamala Mantha-Thaler</last_name>
      <phone>212-420-3450</phone>
      <email>kmantha@chpnet.org</email>
    </contact>
    <investigator>
      <last_name>Leonid Poretsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Chmielewski, CMA, CCRP</last_name>
      <phone>919-688-7863</phone>
      <email>D2dstudy@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Ranee Chatterjee Montgomery, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Kuker, MA, CCRC</last_name>
      <phone>843-792-5427</phone>
      <email>kuker@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick O'Neil, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Jones, RN</last_name>
      <phone>901-448-8400</phone>
    </contact>
    <investigator>
      <last_name>Karen C Johnson, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Brightman</last_name>
      <phone>214-342-2383</phone>
      <email>brenda.brightman@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Philip Raskin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Gee, RD</last_name>
      <phone>713-798-3741</phone>
      <email>VitDstudy@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>John Foreyt, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>August 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prediabetes</keyword>
  <keyword>Vitamin D</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
